Literature DB >> 29078731

Immune regulation effect of lienal polypeptides extract in Lewis lung carcinoma-bearing mice treated with cyclophosphamide.

Yan-Ping Wu1,2, Jie Deng1,2, Shu-Hua Ouyang1,2, Zhong-Fu Mao1,2, Guo-En Wang1,2, Hiroshi Kurihara1,2, Rong-Rong He1,2, Yi-Fang Li1,2.   

Abstract

Polypeptides extracted from animal immune organs have been proved to exert immunomodulatory activities in previous reports. However, relative experimental data regarding the influence of a polypeptide mixture extracted from healthy calf spleen (lienal polypeptide [LP]) on the immune function in tumor therapy are limited, and the components in LP remain unclear. In the present study, the immune regulatory effect of LP was investigated in normal mice and Lewis lung carcinoma (LLC)-bearing mice treated with cyclophosphamide (CTX). The components of LP were identified by liquid chromatography-electrospray ionization-coupled with tandem mass spectrometry (LC-MS/MS) analysis and bioinformatic analysis. In LLC-bearing mice, LP showed a synergic antitumor effect with CTX, whereas LP alone did not present direct antitumor activity. Further, LP was found to enhance immune organ indexes, splenocyte number, and T lymphocyte subsets in normal mice and LLC-bearing mice treated with CTX. The decline of white blood cell and platelet counts, splenocyte proliferation activity, and peritoneal macrophage phagocytic function caused by CTX were also significantly suppressed by LP treatment in LLC-bearing mice. Notably, LP treatment significantly decreased the expression of phagocytosis-related proteins including CD47/signal regulatory protein α/Src homology phosphatase-1 in the tumor tissue of LLC-bearing mice treated with CTX. LC-MS/MS-based peptidomics unraveled the main polypeptides in LP with a length from 8 to 25 amino acids. Bioinformatics analysis further confirmed the possibility of LP to regulate immunity, especially in phagocytosis-related pathway. Our above findings indicated that LP can relieve the immunosuppression induced by chemotherapy and is a beneficial supplement in cancer therapy. Impact statement The immunomodulatory activities of polypeptides extracted from animal immune organs have incurred people's interests since a long time ago. In this study, we investigated the immune regulation effects of a polypeptide mixture extracted from health calf spleen (lienal polypeptide [LP]) in Lewis lung carcinoma-bearing mice treated with cyclophosphamide (CTX). Liquid chromatography-electrospray ionization-coupled with tandem mass spectrometry-based peptidomics and bioinformatics analysis unraveled the main polypeptides in LP and further confirmed that LP is mainly associated with immune regulating pathway, especially in tumor cell phagocytosis-related pathway. Our study for the first time revealed that polypeptides from spleen can relieve the immunosuppression induced by CTX and is a beneficial supplement in cancer therapy.

Entities:  

Keywords:  Lienal polypeptides; antitumor; cyclophosphamide; immunomodulation; peptidomics; phagocytosis

Mesh:

Substances:

Year:  2017        PMID: 29078731      PMCID: PMC5788154          DOI: 10.1177/1535370217737982

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  37 in total

1.  Immuno-enhancement effects of Shenqi Fuzheng Injection on cyclophosphamide-induced immunosuppression in Balb/c mice.

Authors:  Jinxu Wang; Xin Tong; Peibo Li; Hui Cao; Weiwei Su
Journal:  J Ethnopharmacol       Date:  2011-12-27       Impact factor: 4.360

Review 2.  Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.

Authors:  Tadeusz Robak; Ewa Lech-Maranda; Pawel Robak
Journal:  Expert Rev Anticancer Ther       Date:  2010-10       Impact factor: 4.512

3.  The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.

Authors:  Juan Li; Yanna Cheng; Xinke Zhang; Lei Zheng; Zhen Han; Pingli Li; Yuliang Xiao; Qian Zhang; Fengshan Wang
Journal:  Cancer Lett       Date:  2013-05-14       Impact factor: 8.679

Review 4.  Thymopoietin to thymopentin: experimental studies.

Authors:  G Goldstein; T K Audhya
Journal:  Surv Immunol Res       Date:  1985

5.  Studies of thymopoietin pentapeptide (TP5) on experimental tumors. I. TP5 relieves immunosuppression in tumor-bearing mice.

Authors:  C Y Lau; E Y Wang; G Goldstein
Journal:  Cell Immunol       Date:  1982-01-15       Impact factor: 4.868

6.  Protective effect of chitooligosaccharides against cyclophosphamide-induced immunosuppression in mice.

Authors:  Yu-xia Mei; Hong-xia Chen; Jun Zhang; Xue-dan Zhang; Yun-xiang Liang
Journal:  Int J Biol Macromol       Date:  2013-09-27       Impact factor: 6.953

Review 7.  Calreticulin in the immune system: ins and outs.

Authors:  Malini Raghavan; Sanjeeva J Wijeyesakere; Larry Robert Peters; Natasha Del Cid
Journal:  Trends Immunol       Date:  2012-09-07       Impact factor: 16.687

8.  In silico approach for predicting toxicity of peptides and proteins.

Authors:  Sudheer Gupta; Pallavi Kapoor; Kumardeep Chaudhary; Ankur Gautam; Rahul Kumar; Gajendra P S Raghava
Journal:  PLoS One       Date:  2013-09-13       Impact factor: 3.240

9.  Thymosin alpha 1: biological activities, applications and genetic engineering production.

Authors:  Juan Li; Chun Hui Liu; Feng Shan Wang
Journal:  Peptides       Date:  2010-08-10       Impact factor: 3.750

10.  Beneficial effects of 20(S)-protopanaxadiol on antitumor activity and toxicity of cyclophosphamide in tumor-bearing mice.

Authors:  Guangzhu Lin; Xiaofeng Yu; Jing Wang; Shaochun Qu; Dayuan Sui
Journal:  Exp Ther Med       Date:  2012-11-20       Impact factor: 2.447

View more
  2 in total

1.  Experimental Study and Clinical Observation on the Improvement Effect of Lienal Polypeptide on Blood Toxicity and Immune Injury Induced by Radiotherapy.

Authors:  Alan Chu; Rui Song; Ge Hou; Jinjin Yuan; Cheng Wang; Yu Yang; Ning Qin; Yaohe Liu; Bing Liang; Yan Zhang; Zongwen Liu
Journal:  Genet Test Mol Biomarkers       Date:  2020-02

2.  The effectiveness and safety of lienal polypeptide combined with chemotherapy or chemoradiotherapy for non-small cell lung cancer patients in real world.

Authors:  Zhe Wang; Junfeng Liu
Journal:  Medicine (Baltimore)       Date:  2021-01-29       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.